REVIVEPEPTIDES
0

The population the tesamorelin evidence comes from, and why that matters for every claim made about it

Published 26 October 2026 · REVIVE LAB UAE Research Desk · 5 min read
The phase 3 trials of Falutz and colleagues in 2007 and 2010, the liver fat trials of Stanley and colleagues in 2014 and 2019, and nearly every other controlled tesamorelin study enrolled adults with HIV infection on stable antiretroviral therapy with abdominal fat accumulation. Participants were mostly men in their forties and fifties with reduced growth hormone secretion as part of their condition. The one substantial exception is the cognition trial of Baker and colleagues in 2012, which enrolled HIV-negative older adults with and without mild cognitive impairment. Results obtained in a population with a specific disease, a specific drug exposure and a specific endocrine disturbance describe that population.

Why HIV

The company developed the molecule for a condition with an unmet need, a plausible mechanism — blunted growth hormone secretion — and a measurable endpoint. HIV-associated lipodystrophy fitted all three and offered a regulatory path. The choice shaped the evidence base: a few thousand participant-years of data in one disease.

Growth hormone itself had been tried in the same condition with more adverse effects, which favoured the releasing-hormone approach.

What transfers and what does not

Pharmacology — receptor binding, half-life, pituitary dependence, feedback — transfers to anyone with a pituitary. Effect sizes do not transfer automatically: a population with suppressed growth hormone may respond differently from one with normal secretion, and antiretroviral drugs alter fat metabolism. Safety findings in a population with altered immunity and polypharmacy may understate or overstate what would be seen elsewhere. The cognition trial is the only direct evidence outside HIV and it measured cognition, not fat.

This is a statement about evidence, not about the molecule.

Why it is here

Because claims about tesamorelin in people without HIV extrapolate from this base, and a reader should know that. It describes the literature and no use of the pack.

Tesamorelin is supplied by REVIVE LAB UAE for laboratory research use only, with identity by mass spectrometry and purity by HPLC for the batch. It is not for human or veterinary use, and no dosing, administration or protocol guidance is provided.

What it costs

FormatStrengthPriceAvailability
Tesamorelin Pack20 mgAED 1010In stock

Delivery is AED 40 flat and free on orders over AED 700. Payment is cash on delivery anywhere in the UAE, or USDT (TRC20) in advance, which takes 5% off the order total.

Frequently asked

Why HIV?

The company developed the molecule for a condition with an unmet need, a plausible mechanism — blunted growth hormone secretion — and a measurable endpoint. HIV-associated lipodystrophy fitted all three and offered a regulatory path. The choice shaped the evidence base: a few thousand participant-years of data in one disease.

Does REVIVE LAB UAE provide dosing guidance?

No. REVIVE LAB UAE supplies research materials and provides no dosing, administration or protocol guidance of any kind. Every product is sold for laboratory research use only and is not for human or veterinary consumption.

How fast is delivery in the UAE?

Stock is held in Dubai. An order confirmed before 4 PM Dubai time is dispatched the same working day, reaching Dubai and Abu Dhabi the same day and the remaining emirates within 24 hours. Delivery is AED 40 flat and free over AED 700.

Tesamorelin Pack — in stock, dispatched from Dubai
HPLC-verified, lot certificate on every carton, 24-hour delivery nationwide. Browse the catalogue → All peptides UAE

Related reading

→ Tesamorelin Pack — 20 mg → Tesamorelin and HIV lipodystrophy research → Baker 2012: the cognition trial

Supplied for laboratory research use only. Not for human or veterinary consumption. REVIVE LAB UAE provides no dosing, administration or protocol guidance.